Efficacy and safety of crizotinib in patients (pts) with advanced <i>MET</i> exon 14-altered non-small cell lung cancer (NSCLC).

Alexander Drilon, Paul K. Paik, Sai‐Hong Ignatius Ou et al.|Journal of Clinical Oncology|2016

Cited by 113